MRI Intratumoral Heterogeneity Combined with RNA Transcriptomics Predicts Sentinel Lymph Node Metastasis in Clinically Node-Negative Breast Cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500107340

Enrollment

Unknown

Registered

2025-08-08

Start date

2025-08-08

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:intraoperative rapid freezing pathology or postoperative paraffin pathology

Index test:The predictive model developed in this study

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed cN0 breast cancer with documented sentinel lymph node (SLN) status; (2) Complete clinical and pathological records; (3) Absence of concurrent malignancies; (4) Dynamic contrast-enhanced MRI (DCE-MRI) performed within 4 weeks prior to surgery.

Exclusion criteria

Exclusion criteria: (1) Any anticancer therapy administered before MRI and surgery; (2) Non-mass enhancement (NME) pattern on MRI; (3) Significant artifacts compromising image quality; (4) Incomplete clinicopathological data.

Design outcomes

Primary

Measure	Time frame
The Area Under the ROC curve (AUC) of the model;Accuracy;Sensitivity;Specificity;	—

Countries

China

Contacts

Public ContactSu Lv

West China Hospital, Sichuan University

lusuwcums@hotmail.com+86 189 8060 2270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026